^
CANCER:

Adenoid Cystic Carcinoma

Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/22/2021
Initiation :
01/13/2017
Primary completion :
08/01/2022
Completion :
08/01/2022
CD4
|
PD-L1 overexpression • PD-L1 amplification
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 2
Actuate Therapeutics Inc.
Not yet recruiting
Last update posted :
07/20/2021
Initiation :
09/01/2021
Primary completion :
06/01/2023
Completion :
06/01/2024
BCL2
|
carboplatin • 9-ING-41
Phase 1
VM Oncology, LLC
Recruiting
Last update posted :
03/15/2021
Initiation :
06/08/2018
Primary completion :
06/01/2022
Completion :
12/01/2022
NTRK1
|
NTRK1 fusion • NTRK1 mutation • NTRK expression
|
VMD-928
Phase 1/2
Cellestia Biotech AG
Recruiting
Last update posted :
10/07/2020
Initiation :
12/05/2017
Primary completion :
12/21/2021
Completion :
12/21/2021
HER-2
|
CB-103
Phase 2
Dana-Farber Cancer Institute
Completed
Last update posted :
07/21/2020
Initiation :
08/05/2019
Primary completion :
04/15/2020
Completion :
04/15/2020
MYB
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
04/20/2018
Initiation :
03/16/2009
Primary completion :
01/30/2013
KIT
|
KIT expression • KIT overexpression
|
dasatinib
Phase 1
Peter MacCallum Cancer Centre, Australia
Not yet recruiting
Last update posted :
03/29/2018
Initiation :
05/30/2018
Primary completion :
12/30/2019
Completion :
12/30/2022
IFNG • TNFA
|
Baize’an (tislelizumab)
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
04/18/2017
Initiation :
09/01/2004
Primary completion :
02/01/2009
EGFR • HER-2
|
HER-2 expression • EGFR expression
|
lapatinib
Phase 1/2
National Cancer Institute (NCI)
Completed
Last update posted :
06/11/2014
Initiation :
01/01/2005
Primary completion :
10/01/2007
Completion :
05/01/2008
IL2
|
Erbitux (cetuximab) • Avastin (bevacizumab) • erlotinib
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
09/30/2013
Initiation :
12/01/2001
Primary completion :
01/01/2011
HER-2 • ER • PGR
|
ER negative • PGR negative
|
irinotecan • 7-Hydroxystaurosporine (UCN-01)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
02/28/2013
Initiation :
08/01/1999
Primary completion :
02/01/2009
HER-2
|
HER-2 overexpression
|
Herceptin (trastuzumab) • carboplatin • Abraxane (albumin-bound paclitaxel)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
01/16/2013
Initiation :
12/01/2001
Primary completion :
07/01/2007
EGFR
|
EGFR positive
|
erlotinib
Phase 1
Fox Chase Cancer Center
Completed
Last update posted :
07/11/2012
Initiation :
11/01/2008
Primary completion :
07/01/2011
Completion :
07/01/2011
CEACAM5
|
Erbitux (cetuximab) • everolimus